Phase III Multicenter Randomized Trial of Oxaliplatin Added to Chronomodulated Fluorouracil–Leucovorin as First-Line Treatment of Metastatic Colorectal Cancer

Giacchetti, Sylvie; Perpoint, B; Zidani, R.; Bail, N Le; Faggiuolo, R.; Focan, C.; Chollet, Philippe; Llory, J; Letourneau, Y.; Coudert, Bruno; Bertheaut-Cvitkovic, F.; Larregain-Fournier, D.; Rol, A. Le; Walter, Stephen D.; Adam, René; Misset, J.L.; Lévi, Françis

doi:10.1200/jco.2000.18.1.136

Cited by 1,262 publications

(675 citation statements)

References 49 publications

Supporting

Mentioning

619

Contrasting

Unclassified

Order By: Relevance

“…Documented data suggest that OHP as a continuous 6-h infusion seems to decrease the risk of hypersensitivity reactions. Only one out of 100 (1%) patients treated with OHP as a 6-h infusion added to chronomodulated 5-FU -FA as a first-line treatment of advanced colorectal cancer developed hypersensitivity-like reactions (Giacchetti et al, 2000). When OHP is infused in a chronomodulate setting (as a 12-h infusion) or flat infusion for 5 days, these hypersensitivity reactions do not occur.…”

Section: Discussionmentioning

confidence: 99%

Hypersensitivity reactions related to oxaliplatin (OHP)

et al. 2003

View full text Add to dashboard Cite

Patients treated with platinum compounds are subject to hypersensitivity reactions. Our study has highlighted the reactions related to oxaliplatin (OHP) infusion. One hundred and twenty-four patients affected by advanced colorectal cancer were treated with different schedules containing OHP, at the Institute of Haematology and Medical Oncology 'L. and A. Seragnoli' of Bologna and at the Medical Oncology Division of Livorno Hospital. Seventeen patients (13%) showed hypersensitivity reactions after a few minutes from the start of the OHP infusion. Usually, these reactions were seen after 2 -17 exposures to OHP (Mean7s.e.: 9.471.07). No patient experienced allergic reactions at his/her first OHP infusion. Eight patients developed a mild reaction consisting of flushing and swelling of the face and hands, itching, sweating and lachrymation. The remaining nine patients showed a moderatesevere reaction with dyspnoea, wheezing, laryngospasm, psycho-motor agitation, tachycardia, precordial pain, diffuse erythema, itching and sweating. Six patients out of 17 were re-exposed to the drug with premedication of steroids and all except one developed the hypersensitivity reaction again. The cumulative dose, the time of exposure to OHP and the clinical features are variable and unpredictable. The risk of developing hypersensitivity reactions in patients treated with a short infusion of OHP cannot be underestimated.

show abstract

Section: Discussionmentioning

confidence: 99%

Hypersensitivity reactions related to oxaliplatin (OHP)

et al. 2003

View full text Add to dashboard Cite

show abstract

“…Published phase III trials similarly reported that in combination with infusional (de Gramont et al, 2000) or chronomodulated (Giacchetti et al, 2000) 5-FU/FA, a second new agent, oxaliplatin, was also effective first-line in the treatment of advanced CRC. RRs (51 vs 22 and 53 vs 16%, respectively) and median PFS times (9.0 vs 6.2 and 8.7 vs 6.1 months) were improved in the oxaliplatin/5-FU/ FA arms compared to the 5-FU/FA alone arms.…”

Section: Oxaliplatin In the First-line Treatment Of Advanced Crcmentioning

confidence: 99%

Management of advanced colorectal cancer: state of the art

Saunders

Iveson

2006

Br J Cancer

View full text Add to dashboard Cite

Colorectal cancer (CRC) caused over 500 000 deaths worldwide in 2002. Recent advances in the treatment of advanced disease include the incorporation of two new cytotoxic agents, irinotecan and oxaliplatin, into first-line regimens. The concept of planned sequential therapy involving three active agents during the course of a patient's treatment is evolving. Coupled with the integrated use of targeted monoclonal antibodies, we can now expect overall survival rates for advanced disease to exceed 20 months. This review considers current treatments and suggests where future progress may occur.

show abstract

“…62 Oxaliplatin has modest activity as a single agent, but is very active in combination with 5FU/LV, with response rates of approximately 50% seen in first-line treatment of metastatic CRC. 63 Excision repair cross complementing (ERCC) proteins are components of the nucleotide excision repair system. High ERCC1 gene expression has been shown to correlate with poor survival and response of gastric cancer patients treated with 5FU and cisplatin.…”

Section: Platinum Compoundsmentioning

confidence: 99%